IRIS Accounts Production v24.1.4.33 06596885 Board of Directors 1.6.23 31.5.24 31.5.24 4/10/2024 false true false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh065968852023-05-31065968852024-05-31065968852023-06-012024-05-31065968852022-05-31065968852022-06-012023-05-31065968852023-05-3106596885ns15:EnglandWales2023-06-012024-05-3106596885ns14:PoundSterling2023-06-012024-05-3106596885ns10:Director12023-06-012024-05-3106596885ns10:PrivateLimitedCompanyLtd2023-06-012024-05-3106596885ns10:SmallEntities2023-06-012024-05-3106596885ns10:Audited2023-06-012024-05-3106596885ns10:SmallCompaniesRegimeForDirectorsReport2023-06-012024-05-3106596885ns10:SmallCompaniesRegimeForAccounts2023-06-012024-05-3106596885ns10:FullAccounts2023-06-012024-05-3106596885ns10:Director22023-06-012024-05-3106596885ns10:Director32023-06-012024-05-3106596885ns10:Director42023-06-012024-05-3106596885ns10:Director52023-06-012024-05-3106596885ns10:CompanySecretary12023-06-012024-05-3106596885ns10:RegisteredOffice2023-06-012024-05-3106596885ns5:CurrentFinancialInstruments2024-05-3106596885ns5:CurrentFinancialInstruments2023-05-3106596885ns5:Non-currentFinancialInstruments2024-05-3106596885ns5:Non-currentFinancialInstruments2023-05-3106596885ns5:ShareCapital2024-05-3106596885ns5:ShareCapital2023-05-3106596885ns5:SharePremium2024-05-3106596885ns5:SharePremium2023-05-3106596885ns5:FurtherSpecificReserve1ComponentTotalEquity2024-05-3106596885ns5:FurtherSpecificReserve1ComponentTotalEquity2023-05-3106596885ns5:RetainedEarningsAccumulatedLosses2024-05-3106596885ns5:RetainedEarningsAccumulatedLosses2023-05-3106596885ns5:PlantMachinery2023-06-012024-05-3106596885ns5:FurnitureFittings2023-06-012024-05-3106596885ns5:ComputerEquipment2023-06-012024-05-3106596885ns5:PlantMachinery2023-05-3106596885ns5:FurnitureFittings2023-05-3106596885ns5:ComputerEquipment2023-05-3106596885ns5:PlantMachinery2024-05-3106596885ns5:FurnitureFittings2024-05-3106596885ns5:ComputerEquipment2024-05-3106596885ns5:PlantMachinery2023-05-3106596885ns5:FurnitureFittings2023-05-3106596885ns5:ComputerEquipment2023-05-3106596885ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-05-3106596885ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-05-31
REGISTERED NUMBER: 06596885 (England and Wales)


















FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MAY 2024

FOR

APEX MOLECULAR LIMITED

APEX MOLECULAR LIMITED (REGISTERED NUMBER: 06596885)






CONTENTS OF THE FINANCIAL STATEMENTS
for the Year Ended 31 May 2024




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 3


APEX MOLECULAR LIMITED

COMPANY INFORMATION
for the Year Ended 31 May 2024







DIRECTORS: Dr P Jackson
Dr T E O Screen
Dr S A Brown
Dr A Flinn
M Warburton





SECRETARY: S D Hoskins





REGISTERED OFFICE: Block 19 Alderley Park
Mereside
Alderley Edge
Cheshire
SK10 4TG





REGISTERED NUMBER: 06596885 (England and Wales)





AUDITORS: Fairhurst
Statutory Auditor
Chartered Accountants
Douglas Bank House
Wigan Lane
Wigan
Lancashire
WN1 2TB

APEX MOLECULAR LIMITED (REGISTERED NUMBER: 06596885)

STATEMENT OF FINANCIAL POSITION
31 May 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 152,305 335,933

CURRENT ASSETS
Debtors 5 652,674 613,629
Cash at bank and in hand 1,236,916 1,413,259
1,889,590 2,026,888
CREDITORS
Amounts falling due within one year 6 397,848 557,090
NET CURRENT ASSETS 1,491,742 1,469,798
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,644,047

1,805,731

CREDITORS
Amounts falling due after more than one
year

7

-

34,188
NET ASSETS 1,644,047 1,771,543

CAPITAL AND RESERVES
Called up share capital 311,719 311,719
Share premium 647,168 647,168
Other reserves 6,330 6,330
Retained earnings 678,830 806,326
1,644,047 1,771,543

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 4 October 2024 and were signed on its behalf by:





Dr S A Brown - Director


APEX MOLECULAR LIMITED (REGISTERED NUMBER: 06596885)

NOTES TO THE FINANCIAL STATEMENTS
for the Year Ended 31 May 2024

1. STATUTORY INFORMATION

Apex Molecular Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going concern
At the time of approving the financial statements, the directors have a reasonable expectation that the company has sufficient resources to continue in operational existence for the foreseeable future and the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.
Plant and machinery - 25% on reducing balance
Fixtures and fittings - 33% on reducing balance
Computer equipment - 25% on reducing balance

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


APEX MOLECULAR LIMITED (REGISTERED NUMBER: 06596885)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 31 May 2024

2. ACCOUNTING POLICIES - continued

Hire purchase and leasing commitments
Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

Pension costs and other post-retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense to the profit and loss as they fall due.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 38 (2023 - 47 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
Plant and and Computer
machinery fittings equipment Totals
£    £    £    £   
COST
At 1 June 2023 799,846 6,904 26,074 832,824
Additions 26,687 - - 26,687
Disposals (6,482 ) - (791 ) (7,273 )
At 31 May 2024 820,051 6,904 25,283 852,238
DEPRECIATION
At 1 June 2023 474,936 6,613 15,342 496,891
Charge for year 206,104 73 4,139 210,316
Eliminated on disposal (6,482 ) - (792 ) (7,274 )
At 31 May 2024 674,558 6,686 18,689 699,933
NET BOOK VALUE
At 31 May 2024 145,493 218 6,594 152,305
At 31 May 2023 324,910 291 10,732 335,933

The net book value of tangible fixed assets includes £ 25,975 (2023 - £ 83,097 ) in respect of assets held under hire purchase contracts.

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 465,469 420,990
Tax 39,954 80,000
Prepayments 147,251 112,639
652,674 613,629

APEX MOLECULAR LIMITED (REGISTERED NUMBER: 06596885)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 31 May 2024

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts 5,353 2,756
Hire purchase contracts 34,188 51,531
Trade creditors 82,041 151,350
Social security and other taxes 51,785 54,982
VAT 138,751 146,046
Accruals and deferred income 85,730 150,425
397,848 557,090

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2024 2023
£    £   
Hire purchase contracts - 34,188

8. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Jane Dennis BA (Hons) FCA (Senior Statutory Auditor)
for and on behalf of Fairhurst

9. ULTIMATE CONTROLLING PARTY

In the opinion of the directors, there is no ultimate controlling party.